NMS-293 is under clinical development by Nerviano Medical Sciences and currently in Phase II for Astrocytoma. According to GlobalData, Phase II drugs for Astrocytoma have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NMS-293’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NMS-293 is under development for the treatment of recurrent glioblastoma multiforme (GBM), diffuse astrocytoma, oligodendroglioma, glioblastoma multiforme, metastatic HER2 negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer (CRPC) and pancreatic cancer. It is a small molecule. It acts by targeting poly (ADP-ribose) polymerase 1 (PARP-1). The drug candidate is administered through oral route as a hard capsule.
Nerviano Medical Sciences overview
Nerviano Medical Sciences (NMS), a subsidiary of NMS Group SpA, is discovering and developing small molecule NCEs (new chemical entities) for oncology indications. It is primarily focusing on developing inhibitors including encorafenib, for melanoma and colorectal cancer; entrectinib for relapsed/refractory tumors and onvansertib for AML (acute myeloid leukemia) and solid tumors. Its pipeline also includes milciclib and NMS-153 for hepatocellular carcinoma (HCC); NMS-088 for acute myeloid leukemia; and NMS-293 for breast, ovarian, prostate and pancreatic tumors. The company utilizes KINASE and ADC platform technologies to carry out the research and development of its novel treatments. NMS is headquartered in Milan, Lombardy, Italy.
For a complete picture of NMS-293’s drug-specific PTSR and LoA scores, buy the report here.